BioSpace News Archive

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its new INTELLIO Connected Tower Solution which wirelessly connects and remotely controls multiple Sports Medicine systems from outside the sterile field.

The breadth of continued research in plaque psoriasis, psoriatic arthritis, basal cell carcinoma, and actinic keratoses underscores Sun Pharma’s commitment to dermatology HCPs and patients [11-June-2020] PRINCETON, N.J. , June 11, 2020 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (SPII) “Sun Pharma” today announced 25 data abstracts from its dermatology p

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2020 Raymond James Human Health Innovation Conference on June 18, 2020 at 9:40 am Eastern Time. Interested investors can access the live presentation on the Events and Pre

Dyne Therapeutics, a biotechnology company pioneering life-transforming therapies for patients with serious muscle diseases, today announced the appointment of Daniel Wilson as vice president, head of intellectual property

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the addition of four new synthetic SARS-CoV-2 RNA Controls for the development, verification, and ongoing validation of diagnostic tests. The controls include new variants of SARS-CoV-2, the virus that causes COVID-19, expanding the

Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial – – CONTACT-01 is the first of three phase 3 pivotal trials that are part of a previously announced clinical collaboration with Roche –

Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA™ (pegfilgrastim-apgf), a biosimilar to Neulasta ® (pegfilgrastim). 1 NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence

Phase 3 study of 30,000 subjects expected to begin in July 2020 at 100 μg dose level Manufacturing scale up with Lonza on track to supply 500 million to 1 billion 100 μg doses per year Completed enrollment of younger adults in the Phase 2 study of mRNA-1273 (n=300); also completed enrollment of the sentinel group of older adults (n=50)

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company has filed patent applications for a point-of-care device which improves the speed and accuracy of lateral flow immunoassays (LFIA) to detect COVID-19

Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate Agreement valued at approximately $87 million GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s vaccine candidate for